Research shows that most young people who take puberty blockers do progress to gender-affirming hormones, with studies indicating rates of approximately 85-95%. Evidence suggests this progression occurs because the thorough assessment process typically identifies those who genuinely experience persistent gender dysphoria.

Guidelines recommend that puberty blockers are prescribed only after comprehensive evaluation by specialist teams, including mental health professionals, paediatricians, and endocrinologists. This careful screening process means that young people who receive blockers have already demonstrated consistent, persistent gender dysphoria over time. When these individuals later choose hormone therapy, it reflects the accuracy of the original clinical assessment rather than any influence from the blockers themselves.

The timing of progression varies for each person, but typically occurs when their peers are experiencing natural puberty. This approach allows transgender young people to develop secondary sex characteristics that align with their gender identity at an age-appropriate time, helping them integrate socially with their peer group. Research indicates that this timing can significantly improve psychological wellbeing and reduce the distress associated with gender dysphoria.

It's important to understand that this high progression rate doesn't mean puberty blockers automatically lead to hormone therapy. Rather, it demonstrates that the comprehensive assessment process effectively identifies young people who will benefit from continued gender-affirming treatment. For families considering this path, working with experienced gender specialists ensures decisions are made with proper support and expertise.